Clinical Significance of SFRP1 Gene Methylation in Patients with Childhood Acute Lymphoblastic Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.02.010
- Author:
Jing YAN
1
;
Wen-Peng WANG
1
;
Xuan LI
1
;
Wei HAN
1
;
Feng-Qi QI
1
;
Ji-Zhao GAO
2
Author Information
1. Department of Pediatric Hematology and Tumor, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Department of Pediatric Hematology and Tumor, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China,E-mail：xz3765595@163. com.
- Publication Type:Journal Article
- Keywords:
SFRP1;
acute lymphoblastic leukemia;
child;
methylation
- MeSH:
Child;
Humans;
Clinical Relevance;
DNA Methylation;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Bone Marrow/metabolism*;
RNA, Messenger/metabolism*;
Membrane Proteins/genetics*;
Intercellular Signaling Peptides and Proteins/metabolism*
- From:
Journal of Experimental Hematology
2023;31(2):377-382
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical significance of SFRP1 gene and its methylation in childhood acute lymphoblastic leukemia (ALL) .
METHODS:Methylation-specific PCR (MSP) was used to detect the methylation status of SFRP1 gene in bone marrow mononuclear cells of 43 children with newly diagnosed ALL before chemotherapy (primary group) and when the bone marrow reached complete remission d 46 after induction of remission chemotherapy (remission group), the expression of SFRP1 mRNA was detected by quantitative real-time polymerase chain reaction (qRT-PCR), the expression of SFRP1 protein was detected by Western blot, and clinical data of children were collected, the clinical significance of SFRP1 gene methylation in children with ALL was analyze.
RESULTS:The positive rate of SFRP1 gene promoter methylation in the primary group (44.19%) was significantly higher than that in the remission group (11.63%) (χ2=11.328, P<0.05). The relative expression levels of SFRP1 mRNA and protein in bone marrow mononuclear cells of children in the primary group were significantly lower than those in the remission group (P<0.05). Promoter methylation of SFRP1 gene was associated with risk level (χ2=15.613, P=0.000) and survival of children (χ2=6.561, P=0.010) in the primary group, children with SFRP1 hypermethylation had significantly increased risk and shortened event-free survival time, but no significant difference in other clinical data.
CONCLUSION:Hypermethylation of SFRP1 gene promoter may be involved in the development of childhood ALL, and its hypermethylation may be associated with poor prognosis.
